Regeneron Pharmaceuticals today announced financial results for the fourth quarter and full year 2024 and provided a business ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks ...

When the FDA turned down odronextamab in a complete response letter in March, Regeneron said that it was because it had not yet started trials that would be used to confirm accelerated approvals ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Regeneron attempted to downplay the CRLs in a statement, saying that the issue cited in the letters related to the enrolment status of trials that would be used to confirm accelerated approvals ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Regulatory setbacks, including the FDA’s complete response letter for linvoseltamab, further contributed to investor concerns. Analysts' consensus rating on Regeneron Pharmaceuticals stock is ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14 ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...